Efalizumab effective for plaque psoriasis in Latin America

Four poster presentations at the 66th Annual Meeting of the American Academy of Dermatology (AAD) [San Antonio, Texas, US; February 2008] have demonstrated the efficacy and safety of efalizumab [Raptiva] for patients from Latin America with moderate to severe chronic plaque psoriasis, the first evaluation of a biological therapy in such a population. Each poster displayed a different facet of the results, including overall efficacy of efalizumab, efficacy for psoriasis of the hands and feet, and the scalp, and safety and tolerability. For all four analyses, the findings were reported as being consistent with those seen in previous studies of efalizumab in patients with plaque psoriasis conducted in North America and Europe.